IP Library Granted Patent US 9,078,853
Granted Patent B2
US 9,078,853 · App. 13/920,903 · Granted Jul 14, 2015

Dry pharmaceutical compositions for topical delivery of oral medications, nasal delivery and to treat ear disorders

Inventor: Jay Richard Ray, II (Conroe, TX)
Assignee: CMPD LICENSING, LLC
A61K38/14A61K31/351A61K31/4196A61K31/42A61K31/4704A61K31/495A61K31/496A61K31/505A61K31/5383A61K31/56A61K31/575A61K31/7034A61K31/7048A61K31/7052A61K38/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,078,853
App. No.
13/920,903
Granted
Jul 14, 2015
Kind
B2
Abstract

In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent.

Claims (28)

1. An oral rinse formulation or oral solution comprising the following actives in combination with pharmaceutically acceptable excipients or additives:

a) at least one antibiotic in the form of mupirocin;

b) at least one anti-inflammatory steroid in the form of fluticasone;

c) at least one antifungal agent in the form of amphotericin B; and

d) at least one of aluminum hydroxide and/or magnesium hydroxide.

2. The oral rinse formulation or oral solution of claim 1 , wherein the pharmaceutically acceptable excipients or additives include a mouthwash base for use in pharmaceutical compounding and manufacturing of topical preparations.

3. The oral rinse formulation or oral solution of claim 1 , wherein the oral rinse formulation or oral solution does not contain an antihistamine.

4. The oral rinse formulation or oral solution of claim 1 , wherein the fluticasone is present in an amount of 1 to 5 mg per dose.

5. The oral rinse formulation or oral solution of claim 1 , wherein the fluticasone is present in an amount of 15 mg per dose.

6. A method for treating inflammatory, ulcerative and painful conditions of upper alimentary canal mucosal surfaces comprising one of oral mucosa, lip, and perioral region of a patient, the method comprising preparing an oral rinse formulation or oral solution for oral administration into the oral cavity of the patient, and administering the oral rinse formulation or oral solution to the patient, wherein the oral rinse formulation or oral solution comprises the following actives

a) at least one antibiotic in the form of mupirocin,

b) at least one anti-inflammatory steroid in the form of fluticasone, and

c) at least one antifungal agent in the form of amphotericin B.

7. The method of claim 6 , wherein preparing the oral rinse formulation or oral solution for oral administration into the oral cavity of the patient comprises:

forming a dry formulation comprising the a) at least one antibiotic in the form of mupirocin; the b) at least one anti-inflammatory steroid in the form of fluticasone; and the c) at least one antifungal agent in the form of amphotericin B, and

mixing the dry formulation with an oral rinse or base solution material.

8. The method of claim 7 , further comprising:

dispensing the dry formulation to the patient, and wherein the patient subsequently performs the step of mixing the dry formulation with the oral rinse or base solution material to prepare the oral rinse formulation or oral solution.

9. A method for treating inflammatory, ulcerative and painful conditions of upper alimentary canal mucosal surfaces comprising one of oral mucosa, lip, and perioral region of a patient, the method comprising administering to said patient an oral rinse formulation or oral solution comprising at least one antibiotic in the form of mupirocin, at least one anti-inflammatory steroid in the form of fluticasone, and at least one antifungal agent in the form of amphotericin B.

10. The method of claim 9 , wherein administering comprises dispensing the oral rinse formulation or oral solution to the patient to be swished in the mouth of the patient.

11. The method of claim 9 , wherein administering comprises the patient

(1) swishing the oral rinse formulation; and

(2) expectorating the oral rinse formulation.

12. The method of claim 9 , wherein administering comprises the patient

(1) swishing the oral solution; and

(2) swallowing the oral solution.

13. The method of claim 9 , wherein the method further comprises:

preparing the oral rinse formulation or oral solution immediately before administering the formulation to the patient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2014
From: JCDS HOLDINGS, LLC
To: CMPD LICENSING, LLC
Reel/Frame 033795/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2013
From: RAY, JAY RICHARD, II.
To: JCDS HOLDINGS, LLC
Reel/Frame 030640/0231 →
Continuity (1)
Related Publication 20140371134A1 · Dec 18, 2014